• Ko Un Park, Kristin Kyrish, John Terrell, Min Yi, Abigail S Caudle, Kelly K Hunt, Henry M Kuerer, Isabelle Bedrosian, Alastair Thompson, Sarah M DeSnyder, and other members of Department of Breast Surgical Oncology Study Group.
• Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
• J Surg Oncol. 2019 Jun 1; 119 (7): 909-915.

BackgroundFew guidelines exist for an opioid prescription after breast surgical oncology (BSO) procedures. We sought to characterize opioid prescribing and use patterns by surgery type.MethodsPatients (n = 332) undergoing BSO procedure were surveyed one week postoperatively for opioid use. The surgeons were surveyed about pain management preferences surgery type. CPT codes were collected for 2017 to calculate the amount of opioids used by surgery type relative to surgeon preference.ResultsMean oral morphine equivalent (OME) preferred prescription for surgeons who did not tailor prescriptions by surgery type (n = 7, group A) was 177, whereas for those who did tailor (n = 10, group B) varied from 137 to 257 OME. There was a significant difference in opioid use by surgery type: 32 OME for segmental mastectomy (SM) ± sentinel lymph node dissection (SLND), 63 for SM + axillary lymph node dissection (ALND), 76 for total mastectomy (TM) ± SLND, 115 for TM + ALND (P < 0.001). Considering the type of surgeries performed group A prescribers would have 229190 unused OME and group B would have 230826 in 1 year.ConclusionWide variation in opioid use by BSO procedure type was noted with substantial unused OME regardless ofprescribing preference. Evidence-based guidelines are needed to tailor analgesic prescriptions according to the need.© 2019 Wiley Periodicals, Inc.

34 keywords...

hide…